secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0000950170-24-103731
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Fast Track Designation for Perspective's VMT01 in MC1R-positive melanoma
--------------------------------------------------------------------------------

- Fast Track for 212Pb VMT01: diagnosis and treatment of unresectable or metastatic MC1R-positive melanoma.
- Designation enables more frequent FDA interactions and eligibility for accelerated/priority/rolling review.
- Phase 1/2a Cohort 2 DLT observation period completed; safety data to be shared with SMC and scientific forum.
- Company plans to open VMT01/anti-PD-1 combination cohort pending IRB approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017024103731/0000950170-24-103731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017024103731/catx-20240905.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-103731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer